ReviewFrontiers in pharmacology2026
Natural metabolites targeting macrophage polarization for non-small cell lung cancer therapy: a review of mechanisms and applications based on chemical classification.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) accounts for roughly 85% of lung cancer cases and is a leading cause of cancer-related death worldwide. Reprogramming tumor-associated macrophages (TAMs) from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype has emerged as a promising therapeutic strategy. This review examines naturally occurring metabolites that modulate TAM polarization in NSCLC, organized into eight chemical classes: flavonoids, alkaloids, terpenoids, polysaccharides, saponins, stilbenoids, lignans, and phenolic acids. A recurring finding is that these compounds converge on shared signaling pathways, particularly PI3K/Akt/mTOR, NF-κB, and STAT family members, while each class also displays distinct mechanistic tendencies. Flavonoids couple redox modulation with immune effects. Alkaloids engage multiple targets but carry dose-dependent toxicity. Terpenoids show strong tumor microenvironment penetration and synergy with immune checkpoint inhibitors. Polysaccharides act through membrane receptors such as Toll-like receptors and Dectin-1. Saponins largely center on AMPK signaling. The remaining classes, though supported by fewer studies, point to MDSC regulation and context-dependent effects. Multi-component plant extracts and traditional Chinese medicine formulas also influence TAM polarization and have reached adjuvant clinical use. Delivery platforms such as nanoparticles, hydrogels, and exosomes are being developed to address poor bioavailability. Translation remains limited by a lack of trials with TAM-specific endpoints, an oversimplified M1/M2 framework, and the need for standardized pharmacokinetic and targeting assessments. Future progress will require biopsy-based TAM phenotyping, biomarker-driven patient stratification, and delivery systems matched to metabolite properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.